Recursion Pharmaceuticals Inc. Class A Common Stock (RXRX)

About RXRX

Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-…

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Employees

600

Website

www.recursion.com/

Fundamentals

1-day range

$3.31$3.45

Market cap

$1.69B

P/E (trailing)

—

P/E (forward)

-3.73

EPS (trailing)

$-1.04

Dividend yield

—

Beta

1.10

Avg. volume

20.28M

Forecasts

6 analyst ratings

Recursion Pharmaceuticals Inc. Class A Common Stock Competitors

Chosen by industry and closest market cap.

• RXRX

  Recursion Pharmaceuticals Inc. Class A Common Stock

  $3.33

  ▼ 3.20%
  Market cap $1.69BP/E —
  $2.77$7.18
• MESO

  Mesoblast Limited American Depositary Shares

  $17.42

  ▼ 4.18%
  Market cap $1.87BP/E —
  $1.88$3.31
• GLUE

  Monte Rosa Therapeutics Inc. Common Stock

  $13.37

  ▼ 6.63%
  Market cap $1.30BP/E —
  $4.6$25.77
• COAG

  Hemab Therapeutics Holdings Inc. Common Stock

  $44.77

  ▼ 9.55%
  Market cap $2.10BP/E —
  $23$55.42
• INBX

  Inhibrx Biosciences Inc. Common Stock

  $123.93

  ▼ 0.00%
  Market cap $1.21BP/E —
  $26.19$155.29
• IMTX

  Immatics N.V. Ordinary Shares

  $9.45

  ▲ 0.91%
  Market cap $1.21BP/E —
  $5.05$12.41
• VOR

  Vor Biopharma Inc. Common Stock

  $22.66

  ▼ 3.70%
  Market cap $1.16BP/E —
  $6.5$49.95

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Recursion, Novavax and Crispr Stocks Trending in Pre-Market—Here's Why
  benzinga · 8/20/2026
• Tempus AI Just Had Their Entire Strategy Validated By Moderna's Vaccine Advance
  SeekingAlpha · 8/20/2026
• Recursion, Novavax and Crispr Stocks Trending in Pre-Market—Here's Why
  Benzinga · 8/20/2026
• Jim Cramer: These Utilities Stocks Are 'Oversold,' Fastly 'Back From The Abyss'
  Benzinga · 8/13/2026
• These Are the Stocks Wall Street Is Betting Against the Most
  Yahoo · 8/12/2026
• Recursion (RXRX) Q2 2026 Earnings Call Transcript
  Yahoo · 8/12/2026
• The Biggest IPO of the Year Is Targeted in the Next 60 Days. Why One Unexpected Industry Could Rally Before Then (Hint: It’s Not Tech)
  Yahoo · 8/11/2026
• Recursion Pharmaceuticals, Inc. (RXRX) Presents at Bank of America SMID Cap Virtual Conference Transcript
  SeekingAlpha · 8/11/2026
• Recursion Pharmaceuticals: I'm Still Bearish Despite Recent Genentech News
  SeekingAlpha · 8/10/2026

• Blake Borgeson · August 4, 2026 · Sale

  30.0K @ $3.25
• Blake Borgeson · July 7, 2026 · Sale

  40.0K @ $3.96
• Zavain Dar · July 1, 2026 · Grant

  5.1K
• Dean Y. Li · July 1, 2026 · Grant

  3.7K
• Namandje Bumpus · June 18, 2026 · Sale

  4.0K @ $3.18
• Blake Borgeson · June 17, 2026 · Grant

  88.4K
• Franziska Michor · June 17, 2026 · Grant

  88.4K
• Elaine D. Sun · June 17, 2026 · Grant

  88.4K
• Zavain Dar · June 17, 2026 · Grant

  88.4K
• Dean Y. Li · June 17, 2026 · Grant

  88.4K
• Namandje Bumpus · June 17, 2026 · Grant

  88.4K
• Robert Hershberg · June 17, 2026 · Grant

  88.4K
• Ben R. Taylor · June 15, 2026 · Tax Withholding

  5.4K @ $3.15
• Najat Khan · June 5, 2026 · Sale

  23.6K @ $3.58
• Christopher Gibson · June 5, 2026 · Conversion

  40.0K

Institutional Ownership

March 31, 2026

Total shares held

315.01M

Total value held

$959.52M

Institutional holders

332